LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at…Read More
Verona Pharma plc Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE1 Study in COPD at ERS International Congress 2023
